

Open Peer Review on Qeios

Selatinib Ditosilate

National Cancer Institute

Source

National Cancer Institute. <u>Selatinib Ditosilate</u>. NCI Thesaurus. Code C111764.

An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.

Qeios ID: UF00NA · https://doi.org/10.32388/UF00NA